Drug Discovery & Pharmaceuticals

RSS

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

Breakthrough approaches enhance RNA delivery while minimizing inflammation

Lipid nanoparticles (LNPs) are tiny fat bubbles that are used to deliver medicines, genes, and RNA into cells. However, in some cases LNPs can cause harmful inflammation as a result of the process of RNA delivery.

11 Aug 2025

Researchers boost effectiveness of malaria drug by tweaking its symmetry

A new generation of malaria drugs failed clinical trials, in part because they were hard to swallow. UCSF chemists remodeled their structures to make them more soluble, while maintaining their effectiveness against drug-resistant parasites.

11 Aug 2025

AI model can design optimal drug candidates without any prior molecular data

Traditional drug development methods involve identifying a target protein (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) that could bind to that protein and block its function.

11 Aug 2025

Deep learning model predicts adverse drug reactions from chemical structure

Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide. Conventional approaches often fail to detect rare or delayed effects of medicinal products.

7 Aug 2025

KAIST scientists achieve first total synthesis of herpotrichone with neuroprotective properties

"Herpotrichone" is a natural substance that has been evaluated highly for its excellent ability to suppress inflammation in the brain and protect nerve cells, displaying significant potential to be developed as a therapeutic agent for neurodegenerative brain diseases such as Alzheimer's disease and Parkinson's disease.

5 Aug 2025

Promega Plasmid Collection, available through Addgene, equips industry and academic researchers with powerful bioluminescent assays that provide deeper insights into endogenous cellular biology

Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, today announced a strategic partnership with Promega to expand Addgene’s vast plasmid repository with the launch of the Promega Plasmid Collection.

From Promega Corporation 31 Jul 2025

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound.

29 Jul 2025

New model predicts mRNA protein production, accelerating drug and vaccine discovery

A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various cell types. The new advance, developed through an academic-industrial partnership between The University of Texas at Austin and Sanofi, helps predict how much protein cells will produce, which can minimize the need for trial-and-error experimentation, accelerating the next generation of mRNA therapeutics.

26 Jul 2025

Researchers pinpoint PRMT5 as a promising target for cancer drugs

A potential target for experimental drugs that block PRMT5 - a naturally occurring enzyme some tumors rely more on for survival - has been identified by researchers with the Fralin Biomedical Research Institute's Cancer Research Center in Washington, D.C.

26 Jul 2025

New collaborative effort harnesses AI to drive ALS drug discovery in Louisiana

Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases.

23 Jul 2025

PhoreMost demonstrates new approach to rationalize molecular glue drug discovery

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities of its high-throughput GlueSEEKER platform to accelerate the design and development of novel molecular glue degraders.

22 Jul 2025

AI turns old diabetes drug Halicin into a potent weapon against superbugs

Researchers found that Halicin, an AI-identified drug, effectively inhibited most multidrug-resistant bacteria except Pseudomonas aeruginosa. The study highlights Halicin’s broad-spectrum antibacterial potential and the transformative role of artificial intelligence in antibiotic discovery.

20 Jul 2025

Ohio State chemists unlock easier path to develop key drug components

Chemists have developed a novel way to generate a variety of highly useful chemical building blocks by harnessing metal carbenes, suggests new research.

18 Jul 2025

Researchers unveil drug complex that makes cancer cells self-report to immune system

Two junior research groups at Ruhr University Bochum, Germany, have developed a drug complex that kills cancer cells in such a clever manner that they raise a red flag as they die. They signal to the immune system that something is seriously wrong with this type of cell.

18 Jul 2025

Targeting amino acid networks could lead to more precise medicines

Amino acids play a fundamental role in regulating how cells respond to drugs. These molecules, which form proteins, act like bricks that communicate with each other within a structure.

16 Jul 2025

Optogenetic platform enables precise discovery of anti-aging therapeutics

A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases.

16 Jul 2025

Qureight analyze of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results from a collaboration with Insilico Medicine ("Insilico"), a clinical-stage biotechnology company driven by generative AI, focused on rentosertib (ISM001-055), a novel TNIK inhibitor discovered using Insilico's generative AI approach, in development for the treatment of IPF.

16 Jul 2025

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to lung adenocarcinoma cells, dramatically suppressing tumor growth in preclinical models. This approach not only inhibited cancer cell migration and invasion but also showed strong potential for safer, more precise lung cancer therapy.

14 Jul 2025

Vanderbilt and Parse Biosciences team up to develop antibody treatments for measles

Vanderbilt University Medical Center and Parse Biosciences, an innovator in single-cell sequencing, are collaborating on a new treatment to help unvaccinated measles victims, as the U.S. measles outbreak has now reached its highest case count in 30 years.

8 Jul 2025

Drug Discovery & Pharmaceuticals

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Breakthrough approaches enhance RNA delivery while minimizing inflammation

Researchers boost effectiveness of malaria drug by tweaking its symmetry

AI model can design optimal drug candidates without any prior molecular data

Deep learning model predicts adverse drug reactions from chemical structure

KAIST scientists achieve first total synthesis of herpotrichone with neuroprotective properties

Promega Plasmid Collection, available through Addgene, equips industry and academic researchers with powerful bioluminescent assays that provide deeper insights into endogenous cellular biology

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

New model predicts mRNA protein production, accelerating drug and vaccine discovery

Researchers pinpoint PRMT5 as a promising target for cancer drugs

New collaborative effort harnesses AI to drive ALS drug discovery in Louisiana

PhoreMost demonstrates new approach to rationalize molecular glue drug discovery

AI turns old diabetes drug Halicin into a potent weapon against superbugs

Ohio State chemists unlock easier path to develop key drug components

Researchers unveil drug complex that makes cancer cells self-report to immune system

Targeting amino acid networks could lead to more precise medicines

Optogenetic platform enables precise discovery of anti-aging therapeutics

Qureight analyze of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Vanderbilt and Parse Biosciences team up to develop antibody treatments for measles

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Latest Life Science News